Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A disease of the cardiac muscle developed subsequent to the initial protozoan infection by trypanosoma cruzi. After infection, less than 10% develop acute illness such as myocarditis (mostly in children). The disease then enters a latent phase without clinical symptoms until about 20 years later. Myocardial symptoms of advanced chagas disease include conduction defects (heart block) and cardiomegaly.
Biomarker and diagnostic research for Chagas cardiomyopathy has been reported in the published literature.
2 clinical trials registered. Interventions under study include medical devices. Pipeline includes 1 PHASE3, 1 NA. Research is primarily sponsored by academic and government institutions.
223 publications have been identified in PubMed for Chagas cardiomyopathy. Research spans Basic Science / Preclinical (28%), Epidemiology / Natural History (21%), and Review / Meta-Analysis (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 63 | 28% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 11:21 AM UTC
Common questions about Chagas cardiomyopathy
Disease patterns and progression | 47 | 21% |
Research summaries | 37 | 17% |
Clinical study results | 26 | 12% |
Patient case studies | 20 | 9% |
Testing and diagnosis research | 13 | 6% |
Other research | 9 | 4% |
New treatment approaches | 8 | 4% |
Johnson A (2026). [PMID: 42257910](https://pubmed.ncbi.nlm.nih.gov/42257910/). *Heart Fail Rev*. [Review / Meta-Analysis]
Patané JSL (2026). [PMID: 42258512](https://pubmed.ncbi.nlm.nih.gov/42258512/). *PLoS Negl Trop Dis*. [Diagnostic / Biomarker]
Choudhuri S (2026). [PMID: 41672427](https://pubmed.ncbi.nlm.nih.gov/41672427/). *Emerg Microbes Infect*. [Basic Science / Preclinical]
Lobo de Sousa Marques I (2026). [PMID: 42082306](https://pubmed.ncbi.nlm.nih.gov/42082306/). *Curr Top Membr*. [Review / Meta-Analysis]
Hosannah da Silva E Silva MR (2026). [PMID: 41818258](https://pubmed.ncbi.nlm.nih.gov/41818258/). *PLoS Negl Trop Dis*. [Case Report / Case Series]
Rao X (2026). [PMID: 41519395](https://pubmed.ncbi.nlm.nih.gov/41519395/). *The Journal of infection*. [Basic Science / Preclinical]
Lopes RD (2026). [PMID: 41335448](https://pubmed.ncbi.nlm.nih.gov/41335448/). *JAMA*. [Review / Meta-Analysis]
Dinatale B (2026). [PMID: 42070329](https://pubmed.ncbi.nlm.nih.gov/42070329/). *Semin Immunol*. [Review / Meta-Analysis]
Bisio MMC (2026). [PMID: 42239543](https://pubmed.ncbi.nlm.nih.gov/42239543/). *Front Cell Infect Microbiol*. [Diagnostic / Biomarker]
Ariza-Ordóñez N (2026). [PMID: 41924619](https://pubmed.ncbi.nlm.nih.gov/41924619/). *Front Cardiovasc Med*. [Diagnostic / Biomarker]